HB8000, titled the END 7-OH Act, would amend the federal Controlled Substances Act to place synthetic 7-hydroxymitragynine on Schedule I. Schedule I is the most restrictive category under federal drug law, reserved for substances Congress deems to have a high potential for abuse and no accepted medical use. The bill specifically targets synthetic equivalents of 7-hydroxymitragynine, while carving out the naturally occurring form of the compound when it is contained in the kratom plant (Mitragyna speciosa Korth).
In practical terms, the bill would make the manufacture, distribution, and possession of synthetic 7-hydroxymitragynine subject to the strict federal controls and criminal penalties that apply to Schedule I substances. It would not, by its text, ban kratom itself or the naturally occurring compound found in the plant, but it would create a clear federal distinction between natural kratom-derived material and synthetic versions of the alkaloid. The bill would therefore affect manufacturers, distributors, retailers, and consumers of products containing synthetic 7-OH, as well as federal enforcement agencies responsible for controlled substances regulation.
Impact
The bill would amend section 202(c) of the Controlled Substances Act, adding synthetic 7-hydroxymitragynine to Schedule I while expressly excluding naturally occurring 7-hydroxymitragynine in kratom. This would expand federal controlled-substance law to cover a specific synthetic compound and its equivalents, increasing enforcement authority and potential criminal liability for synthetic 7-OH products. It would also create a statutory distinction that may affect how kratom-related products are regulated, marketed, and litigated under federal law.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the overall sentiment appears to be precautionary and enforcement-oriented rather than contested in the available record. The bill’s title and structure suggest a policy goal of stopping distribution of synthetic 7-OH while preserving an exception for natural kratom-derived material. No formal vote history or transcript evidence is provided to show broader support or opposition.
Contention
The main point of contention is likely the line the bill draws between synthetic 7-hydroxymitragynine and naturally occurring 7-hydroxymitragynine in kratom. Supporters would likely view the measure as a targeted public-safety response to a potentially dangerous synthetic opioid-like substance, while critics may argue that Schedule I placement is overly broad, could complicate regulation of kratom-adjacent products, or may be used to justify broader restrictions in the future. Because no committee transcripts or votes are included, specific member positions are not available.
Adding and removing certain substances in schedules I, III and IV of the uniform controlled substances act and making conforming changes to the criminal code definition of fentanyl-related controlled substances.